Chemotherapy Induced Anemia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Chemotherapy Induced Anemia – Pipeline Review, H2 2017’, provides an overview of the Chemotherapy Induced Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia

The report reviews pipeline therapeutics for Chemotherapy Induced Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chemotherapy Induced Anemia therapeutics and enlists all their major and minor projects

The report assesses Chemotherapy Induced Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Chong Kun Dang Pharmaceutical Corp

Galenica Ltd

Novartis AG

Panacea Biotec Ltd

Pfizer Inc

PharmaEssentia Corp

PhytoHealth Corp

SBI Pharmaceuticals Co Ltd

Therapure Biopharma Inc

Tolero Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chemotherapy Induced Anemia - Overview

Chemotherapy Induced Anemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chemotherapy Induced Anemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development

3SBio Inc

Chong Kun Dang Pharmaceutical Corp

Galenica Ltd

Novartis AG

Panacea Biotec Ltd

Pfizer Inc

PharmaEssentia Corp

PhytoHealth Corp

SBI Pharmaceuticals Co Ltd

Therapure Biopharma Inc

Tolero Pharmaceuticals Inc

Chemotherapy Induced Anemia - Drug Profiles

(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin zeta biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric carboxymaltose - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegylated erythropoietin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHEP-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSS-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBI-304H - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-0184 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chemotherapy Induced Anemia - Dormant Projects

Chemotherapy Induced Anemia - Discontinued Products

Chemotherapy Induced Anemia - Product Development Milestones

Featured News & Press Releases

Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H

Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia

Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health

Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology

Oct 21, 2011: ALA Study Results Presented at 39th Annual Meeting of Japanese Association for Acute Medicine

Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting

Oct 03, 2011: ALA Study Results Presented at Japanese Society of Parasitology, 71st Meeting

Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology

Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended

Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world’s first complex biosimilar

Jan 07, 2008: Sandoz and Gambro form strategic alliance

Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chemotherapy Induced Anemia, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Chemotherapy Induced Anemia – Pipeline by 3SBio Inc, H2 2017

Chemotherapy Induced Anemia – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017

Chemotherapy Induced Anemia – Pipeline by Galenica Ltd, H2 2017

Chemotherapy Induced Anemia – Pipeline by Novartis AG, H2 2017

Chemotherapy Induced Anemia – Pipeline by Panacea Biotec Ltd, H2 2017

Chemotherapy Induced Anemia – Pipeline by Pfizer Inc, H2 2017

Chemotherapy Induced Anemia – Pipeline by PharmaEssentia Corp, H2 2017

Chemotherapy Induced Anemia – Pipeline by PhytoHealth Corp, H2 2017

Chemotherapy Induced Anemia – Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017

Chemotherapy Induced Anemia – Pipeline by Therapure Biopharma Inc, H2 2017

Chemotherapy Induced Anemia – Pipeline by Tolero Pharmaceuticals Inc, H2 2017

Chemotherapy Induced Anemia – Dormant Projects, H2 2017

Chemotherapy Induced Anemia – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Chemotherapy Induced Anemia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports